Incidence of atazanavir- associated adverse drug reactions in second -line drugs treated south Indian HIV-1 infected patients

BACKGROUND: Ritonavir-boosted atazanavir (ATV/r) is the preferred second-line protease inhibitor (PI) option for HIV patients in resource-limited settings; its pattern of adverse drug reactions (ADRs) has not been much reported from India; hence, in this study, we have analyzed the incidence of ATV/...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Indian J Pharmacol
Prif Awduron: Subashini, Dhakshinamoorthy, Dinesha, Thongadi Ramesh, Boobalan, Jayaseelan, Samuel, Lawrence Christopher, Poongulali, Selvamuthu, Pradeep, Ambrose, Solomon, Sunil Suhas, Solomon, Suniti, Balakrishnan, Pachamuthu, Saravanan, Shanmugam
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Medknow Publications & Media Pvt Ltd 2016
Pynciau:
Short Communication
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5051255/
https://ncbi.nlm.nih.gov/pubmed/27721547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0253-7613.190759
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg